Describe how fenbendazole targets the p53-glycolysis axis.
By targeting the p53-glycolysis axis fenbendazole pushes cancer cells into an energetic crisis.
Fenbendazole targets the p53-glycolysis axis by linking the activation of a critical tumor suppressor gene directly to the disruption of a cancer cell’s energy metabolism. Here is how this process unfolds:
Upregulation and Activation of p53: Fenbendazole significantly upregulates the expression of the wild-type p53 tumor suppressor protein and promotes its translocation to the mitochondria.
Downregulation of Glycolytic Targets: Once activated, the p53 signaling pathway acts as a switch to suppress aerobic glycolysis, also known as the Warburg effect. It specifically downregulates the expression of glucose transporters (such as GLUT1) to prevent glucose from entering the cell, and strongly inhibits the expression of hexokinase 2 (HK2), the first critical enzyme in the glycolytic pathway.
Metabolic Starvation: By impeding these specific targets, fenbendazole drastically reduces the cancer cell’s glucose consumption, limits lactate production, and depletes intracellular ATP levels, effectively starving the tumor of energy.
Experimental Confirmation: The direct molecular link between p53 and this metabolic disruption was confirmed in laboratory studies in which knockdown of p53 in cancer cells partially reversed fenbendazole’s ability to inhibit HK2 expression, reduce glucose consumption, and deplete ATP.
Ultimately, by targeting the p53-glycolysis axis with HK2 as the primary downstream effector, fenbendazole pushes cancer cells into an energetic crisis. This starvation acts as the molecular trigger that executes terminal cell death mechanisms, including apoptosis and the highly inflammatory pyroptosis discussed earlier.